Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life

References

• GaoMNettlesREBelemaMChemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature201046572949610020410884
   PubMed Web of Science ®Google Scholar
• FridellRAQiuDWangCValeraLGaoMResistance analysis of the hepatitis C virus NS5A inhibitor BS-790052 in an in vitro replicon systemAntimicrob Agents Chemother20105493641365020585111
   PubMed Web of Science ®Google Scholar
• BifanoMHwangCOosterhuisBAssessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovirAntivir Ther201318793194023963204
   PubMed Web of Science ®Google Scholar
• BifanoMSevinskyHHwangCEffect of coadministration of daclatasvir on the pharmacokinetics of combined oral contraceptive containing ethinyl estradiol and norgestimateAntivir Ther201419551151924343001
   PubMed Web of Science ®Google Scholar
• SofiaMJBaoDChangWDiscovery of a beta-d-2′-deoxy-2′-alfa-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virusJ Med Chem201053197202721820845908
   PubMed Web of Science ®Google Scholar
• GaneEJStedmanCAHylandRHNucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CN Engl J Med20133681344423281974
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationDrug safety communication concerning hepatitis C treatments containing sofosbuvir in combination with another direct acting antiviral drug: serious slowing of heart rate when used with antiarrhythmic drug amiodarone Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439662.htmAccessed June 27, 2015
   Google Scholar
• SulkowskiMSGardinerDFRodriguez-TorresMDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionN Engl J Med2014370321122124428467
   PubMed Web of Science ®Google Scholar
• NelsonDRCooperJNLalezariJPAll-oral 12 week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyHepatology20156141127113525614962
   PubMed Web of Science ®Google Scholar
• JensenDMO’LearyJGPockrosPJSafety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal, observational cohortAbstract 45 presented at the 65th Annual Meeting of American Association for the Study of Liver DiseasesBoston, MA, USANovember 7–11, 2014
   Google Scholar
• DieterichDBaconBRFlammSLEvaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous populationAbstract 46 presented at the 65th Annual Meeting of the American Association for the Study of Liver DiseasesBoston, MA, USANovember 7–11, 2014
   Google Scholar
• PolSBourliereMLucierSSafety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHERAbstract L03 presented at 50th Annual Meeting of the European Association for the Study of the LiverVienna, AustriaApril 22–26, 2015
   Google Scholar
• FontaineHHezodeCZoulimFEfficacy of the oral sofosbuvir-based combinations in HCV genotype 4-monoinfected patients from the french observational cohort ANRS CO22 HepatherAbstract LP28 presented at the 50th Annual Meeting of European Association for the Study of the LiverVienna, AustriaApril 22–26, 2015
   Google Scholar
• HezodeCDe LedinghenVFontaineHDaclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use programAbstract LP05 presented at the 50th Annual Meeting of European Association for the Study of the LiverVienna, AustriaApril 22–26, 2015
   Google Scholar
• BuggischJPSarrazinCMaussSSofosbuvir-based treatment under real life conditions in Germany (The SOFGER Trial)Abstract LP0777 presented at the 50th Annual Meeting of the European Association for the Study of the LiverVienna, AustriaApril 22–26, 2015
   Google Scholar
• FlammSLEversonGTCharltonMLedipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective multicenter studyAbstract 239 presented at the 65th Annual Meeting of the American Association for the Study of Liver DiseasesBoston, MA, USANovember 7–11, 2014
   Google Scholar
• BourliereMBronowickiJPde LedinghenLedipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Lancet Infect Dis201541539740425773757
   PubMed Web of Science ®Google Scholar
• WylesDRuanePSulkowskiMDaclatasvir in combination with Sofosbuvir for HIV/HCV coinfection: ALLY-2 studyAbstract 151LB presented at the 22nd Annual Conference on Retroviruses and Opportunistic InfectionsSeattle, Washington, USAFebruary 23–26, 2015
   Google Scholar
• FontanaRJHughesEABifanoMSofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis CAm J Transplant20131361601160523593993
   PubMed Web of Science ®Google Scholar
• PellicelliAMMontalbanoMLionettiRSofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given lateDig Liv Dis20144610923927
   Web of Science ®Google Scholar
• LeroyVDumortierJCoillyAHigh rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: the ANRS CO23 CUPILT studyAbstract 21 presented at the 65th Annual Meeting of the American Association for the Study of Liver DiseasesBoston, MA, USANovember 7–11, 2014
   Google Scholar
• American Association for the Study of Liver Diseases/Infectious Diseases Society of America/International Antiviral Society-USARecommendations for testing, managing, and treating hepatitis C Available from: http://www.hcvguidelines.orgAccessed June 27, 2015
   Google Scholar
• European Association for the Study of the LiverEASL recommendations on treatment of hepatitis C 2015J Hepatol201563119923625911336
   PubMed Web of Science ®Google Scholar